other material
confidence high
sentiment positive
materiality 0.75
ChromaDex expands Nestlé Health Science supply deal to supplements; Nestlé invests $5M
Niagen Bioscience, Inc.
- New 5-year supply agreement gives Nestlé non-exclusive rights to sell Niagen in dietary supplements, medical nutrition, and functional foods.
- Nestlé commits to initial $1.975M Niagen purchase in 2022; ChromaDex eligible for low-single-digit royalties and low-seven-figure milestone payments.
- Nestlé purchases 3,816,794 shares of CDXC at ~$1.31/share for $5M in a registered direct offering.
- Agreement expands prior 2018 deal; term automatically extends if minimum purchase met.